Neuropeptide S (NPS) as a Treatment for Anxiety, Sleep Disorders, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, and Asthma

Background: Patent "WO02/31145" discloses a newly deorphanized GPCR system, Neuropeptide S (NPS), the endogenous ligand, and its cognate GPCR. However this patent does not detail the pharmacological or physiological function of NPS and its GPCR. University of California, Irvine researchers have characterized NPS's function in the CNS. Technology: University of California, Irvine researchers have shown that central administration of NPS increases locomotor activity in mice and decreases paradoxical (REM) sleep and slow wave sleep in rats. NPS was further shown to produce anxiolytic-like effects in mice exposed to different stressful paradigms. Application: The NPS receptor may be used as a system to assay for agonists that are useful therapeutic agents in narcolepsy, hypersomnia or under conditions when elevated alertness is required. Antagonists to the NPS receptor may also be assayed for novel therapeutic approach to treat insomnia. NPS may also be used in the treatment or prevention of asthma and it also may be used as a therapeutic in Attention Deficit Hyperactivity Disorder (ADHD) and Attention Deficit Disorder (ADD).

Type of Offer: Licensing

Next Patent »
« More Biotech Patents
« More Pharmaceutical Patents

Share on      

CrowdSell Your Patent